PharmaMar’s research efforts have been recognized through grants from public entities for several projects, both individual and in cooperation with public centers and private companies.
Marine microbiome against cancer. Reference: RTC-2017-6405-1
The MarBiom project aims to assess the capacity of the cultivable marine microbiome to identify novel molecules with antitumor activity, basically polyketide metabolites and non-ribosomal peptides. It will also allow the application of new genomic, biochemical and analytical techniques to advance the discovery of new antitumor molecules.
Mediterranean Institute of Advanced Studies
Zaidín Experimental Station
University of Almería
A new patient-derived circulating micrometastases-on-chip platform for drug screen and validation. Reference: PLEC2021-008106.
The µMETonChip project develops an innovative micro-system using a chip format with patient-derived circulating tumor cells and micrometastases. Furthermore, the different cell types and micrometastases are tested, as well as the efficacy of natural marine compounds as potential drugs for metastatic cancer patients.
Innovative Therapies for Children with Cancer – Pediatric Preclinical POC Platform. Reference: 116064. Call: IMI2-2015-07-05 “A comprehensive ‘pediatric preclinical POC platform’ to enable clinical molecule development for children with cancer”
The project aims to establish a preclinical study platform that increases therapeutic success of oncology drugs in children with solid malignancies. It is leaded by the Deutsches Krebsforschungszentrum (DKFZ).
Sustainable Exploitation of bio-based Compounds Revealed and Engineered from Natural Sources. Proposal Number: 101000794-2. Call: H2020-FNR-2020-2
The Project aims to fully exploit the potential of aquatic biotechnology and produce novel industrial products for the agrochemical, pharmaceutical, cosmetic and chemistry sectors. SECRETed will develop novel hybrid molecules with tailor-made properties. It is leaded by Optimización Orientada a la Sostenibilidad.
Clinical and pharmacokinetic, open-label, dose-scalation Phase I study of PM14 after intravenous administration to patients with advanced solid tumors. IDI-20170558
The project includes a clinical, open-label and dose-scalation Phase I study for PM14. It is the first clinical study for this compound. The primary goal of the study is to determine the limiting toxicities, maximum tolerated dose and recommended dose of PM14 after intravenous administration to patients with advanced solid tumors. Besides, the project aims to assess the safety and tolerability of PM14, define its pharmacokinetic profile, make pharmacogenomic analysis and obtain preliminary information about the antitumour activity of this compound.